Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PEPD | P12955 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071810 | 0.82 | PEPD (0.44) | MMP2ANPEPBRD4CYP2C19ALDH1A1 | |
| SCHEMBL12225959 | 0.82 | PEPD (0.44) | MMP2ANPEPBRD4CYP2C19ALDH1A1 | |
| SCHEMBL12860964 | 0.82 | PEPD (0.44) | MMP2ANPEPBRD4CYP2C19ALDH1A1 | |
| SCHEMBL12860970 | 0.82 | PEPD (0.44) | MMP2ANPEPBRD4CYP2C19ALDH1A1 | |
| SCHEMBL13865290 | 0.79 | ANPEP (0.49) | MMP2ANPEPBRD4ALDH1A1CYP1A2 | |
| SCHEMBL13865294 | 0.78 | ATM (0.34) | ALDH1A1MAPT | |
| SCHEMBL16401070 | 0.78 | ATM (0.34) | ALDH1A1MAPT | |
| SCHEMBL12765089 | 0.77 | — | — | |
| SCHEMBL10794700 | 0.77 | — | — | |
| SCHEMBL12891657 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131444-A1 | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131444-A1 | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity | AAAS, AMPD2, AMPD3 | MMP2 2536/4885ANPEP 63/4885BRD4 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.